Clinical Trial Update: Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating donor natural killer cells plus aldesleukin in high-risk acute myeloid leukemia patients undergoing donor stem cell transpla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aldesleukin (interleukin-2)
• Donor natural killer cells

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-07-03